Francesco Paoloni

Ancona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Journal: Tumori

Published: May 04, 2026

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 16, 2026

Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report.

Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 16, 2026

Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.

Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.

Journal: The oncologist

Published: February 16, 2026

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 02, 2026

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 02, 2026

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 17, 2025

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Journal: JCO precision oncology

Published: December 05, 2025

Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation.

Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation.

Journal: Current oncology reports

Published: August 02, 2025

Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors.

Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors.

Journal: Scientific reports

Published: June 20, 2025

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 10, 2025

Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.

Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 26, 2025

Showing 1-12 of 20

Last Updated: 09/26/2026